Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors

详细信息    查看全文

• 作者：Marcello Arca ; ^{marcello.arca@uniroma1.it}
• 关键词：Heterozygous familial hypercholesterolemia ; Low-density lipoprotein cholesterol ; Cardiovascular risk ; PCSK9 inhibitors ; Alirocumab ; Evolocumab
• 刊名：Atherosclerosis
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：256
• 期：Complete
• 页码：134-145
• 全文大小：1361 K
• 卷排序：256

文摘

Familial hypercholesterolemia (HeFH) is associated with high risk of coronary heart disease, stroke, peripheral vascular disease. Achieving target LDL-C levels in individuals with HeFH remains a challenge. Recently, monoclonal antibodies against PCSK9, alirocumab and evolocumab, have been developed. These antibodies administered in HeFH further reduce LDL-C.